Horizon Discovery Group PLC (LON:HZD)‘s stock had its “buy” rating reiterated by analysts at Panmure Gordon in a research note issued on Monday. They presently have a GBX 205 ($2.67) target price on the stock. Panmure Gordon’s target price indicates a potential downside of 0.49% from the stock’s previous close.

A number of other brokerages have also recently commented on HZD. Beaufort Securities reaffirmed a “speculative buy” rating on shares of Horizon Discovery Group PLC in a report on Wednesday, January 25th. Numis Securities Ltd reissued a “buy” rating and set a GBX 262 ($3.41) price target on shares of Horizon Discovery Group PLC in a report on Thursday, March 2nd. Finally, N+1 Singer reissued a “buy” rating and set a GBX 194 ($2.52) price target on shares of Horizon Discovery Group PLC in a report on Tuesday, March 14th.

Shares of Horizon Discovery Group PLC (LON:HZD) traded up 4.37% during trading on Monday, hitting GBX 215.00. The stock had a trading volume of 185,561 shares. The firm’s market capitalization is GBX 202.36 million. Horizon Discovery Group PLC has a 1-year low of GBX 104.00 and a 1-year high of GBX 218.00. The stock’s 50-day moving average price is GBX 202.37 and its 200 day moving average price is GBX 166.07.

ILLEGAL ACTIVITY NOTICE: “Horizon Discovery Group PLC’s (HZD) Buy Rating Reaffirmed at Panmure Gordon” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/05/22/horizon-discovery-group-plcs-hzd-buy-rating-reaffirmed-at-panmure-gordon.html.

Horizon Discovery Group PLC Company Profile

Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company’s gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.

12 Month Chart for LON:HZD

Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.